Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

NCT05482789 on ClinicalTrials.gov · last registry update 2026-04-20

A small phase 4 — 13 participants, against a typical 75. The sponsor logged completion for 31 December 2025. Primary outcome, as filed: Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose.

Status: RECRUITING
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Maisa N. Feghali, MD
Sponsor type: Other
Enrollment: 13
Started: 2023-04-12
Primary completion: 2025-12-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose

Conditions studied

Gestational Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.